An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.

MLA

Stadler, Walter M., et al. “An Open-Label, Single-Arm, Phase 2 Trial of the Polo-like Kinase Inhibitor Volasertib (BI 6727) in Patients with Locally Advanced or Metastatic Urothelial Cancer.” Cancer, vol. 120, no. 7, Apr. 2014, pp. 976–82. EBSCOhost, https://doi.org/10.1002/cncr.28519.

APA

Stadler, W. M., Vaughn, D. J., Sonpavde, G., Vogelzang, N. J., Tagawa, S. T., Petrylak, D. P., Rosen, P., Lin, C.-C., Mahoney, J., Modi, S., Lee, P., Ernstoff, M. S., Su, W.-C., Spira, A., Pilz, K., Vinisko, R., Schloss, C., Fritsch, H., Zhao, C., & Carducci, M. A. (2014). An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer, 120(7), 976–982. https://doi.org/10.1002/cncr.28519

Chicago

Stadler, Walter M, David J Vaughn, Guru Sonpavde, Nicholas J Vogelzang, Scott T Tagawa, Daniel P Petrylak, Peter Rosen, et al. 2014. “An Open-Label, Single-Arm, Phase 2 Trial of the Polo-like Kinase Inhibitor Volasertib (BI 6727) in Patients with Locally Advanced or Metastatic Urothelial Cancer.” Cancer 120 (7): 976–82. doi:10.1002/cncr.28519.